| 仇 军,周继朴,高才达,毛 燕,张 勇.五子参药汤治疗COPD稳定期肺脾两虚、痰浊内蕴证的临床观察[J].现代生物医学进展英文版,2021,(2):311-315. |
| 五子参药汤治疗COPD稳定期肺脾两虚、痰浊内蕴证的临床观察 |
| Clinical Observation of Wuzishen Medicine Decoction in Treating the Syndrome of Deficiency of Lung and Spleen and Internal Accumulation of Turbid Phlegm |
| Received:July 04, 2020 Revised:July 27, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.02.024 |
| 中文关键词: 五子参药汤 慢性阻塞性肺疾病 肺脾两虚 痰浊内蕴 稳定期 |
| 英文关键词: Wuzishenyao Decoction Chronic obstructive pulmonary disease Deficiency of both lung and spleen Internal accumulation of turbid phlegm Stable phase |
| 基金项目:国家自然科学基金青年基金项目（81804090） |
|
| Hits: 989 |
| Download times: 585 |
| 中文摘要: |
| 摘要 目的：本文旨在推广高才达主任医师治疗慢性阻塞性肺病稳定期的临床经验，以及观察五子参药汤治疗慢性阻塞性肺疾病稳定期属肺脾两虚、痰浊内蕴症的临床疗效。方法：随机选取我院慢性阻塞性肺疾病（稳定期）患者90例分为对照组（n=45）和治疗组（n=45），对照组吸入沙美特罗替卡松粉气雾剂进行治疗，治疗组在对照组基础上加服五子参药汤，两组疗程均为12 w。对比两组治疗前后临床症状、肺功能、慢阻肺患者自我评估测试（CAT量表）、改良版英国医学研究委员会呼吸问卷（mMRC）量表及治疗后6个月内因COPD急性加重的再次住院次数。结果：治疗组的有效率优于对照组（91.11 % vs 82.45 %，P＜0.05）；治疗后，两组第1秒用力呼气容积（FEV1）、FEV1占预计值百分比(FEV1%)和FEV1/FVC较治疗前均有增加，且治疗组高于对照组（P＜0.05）；两组mMRC量表、CAT量表评分较治疗前均有下降，且治疗组低于对照组（P＜0.05）。结论：五子参药汤可有效治疗肺脾两虚、痰浊内蕴型稳定期慢性阻塞性肺疾病，值得临床推广。 |
| 英文摘要: |
| ABSTRACT Objective: This article aims to promote the clinical experience of Chief Physician Gao Caida in the treatment of stable chronic obstructive pulmonary disease, and to observe the clinical efficacy of Wuzishenyao Decoction in the treatment of stable chronic obstructive pulmonary disease, which is deficiency of both lung and spleen and turbid phlegm. Methods: Ninety patients with chronic obstructive pulmonary disease (stable phase) in our hospital were randomly selected and divided into a control group (n=45) and a treatment group (n=45). The control group was treated by inhaling salmeterol and ticasone powder aerosol. The treatment group was treated with Wuzishenyao Decoction on the basis of the control group. The treatment course of two groups was 12 weeks. The clinical symptoms, lung function, COPD patient self-assessment test (CAT scale), modified version of the British Medical Research Council Respiratory Questionnaire (mMRC) scale before and after treatment were compared between the two groups before and after treatment, and rehospitalization due to acute exacerbation of COPD within 6 months after treatment frequency. Results: The effective rate of the treatment group was better than that of the control group (91.11 % vs 82.45 %, P<0.05). After treatment, the forced expiratory volume in the first second (FEV1), the percentage of FEV1 to the predicted value (FEV1%) and FEV1/FVC in the two groups compared with the previous treatment, the treatment group was higher than the control group (P<0.05). The scores of the mMRC scale and CAT scale of the two groups were lower than before treatment, and the treatment group was lower than the control group (P<0.05). Conclusion: Wuzishenyao Decoction can effectively treat stable chronic obstructive pulmonary disease with deficiency of both lung and spleen and turbid phlegm, which is worthy of clinical promotion. |
|
View Full Text
View/Add Comment Download reader |
| Close |
